Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | ACE | P12821 | 1/20 | 0.56 |
| ▸ | CTSS | P25774 | 3/20 | 0.55 |
| ▸ | CTSK | P43235 | 2/20 | 0.55 |
| ▸ | CTSL | P07711 | 1/20 | 0.55 |
| ▸ | CTSB | P07858 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 4/20 | 0.50 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447452 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL288838 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL3837973 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL743357 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL15775826 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL825622 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL7356486 | 1.00 | KLK5 (0.61) | KLK5ATMACECTSSCTSK | |
| SCHEMBL4275825 | 0.92 | KLK5 (0.58) | KLK5ATMACECTSSCTSK | |
| SCHEMBL4955577 | 0.92 | KLK5 (0.58) | KLK5ATMACECTSSCTSK | |
| SCHEMBL6343884 | 0.90 | KLK5 (0.60) | KLK5ATMACECTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7307184-B2 | Processes for preparing oxazolidinone derivatives of β-hydroxyethlamine compounds and for preparing β-hydroxyethlamine compounds | KANEKA CORPORATION (JP) | 2007-12-11 | — | — | US | disclosed |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7169932-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | PFIZER INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| EP-1739082-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | Agouron Pharmaceuticals , Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| US-20020026081-A1 | Process for producing alpha-aminoketone derivatives | AJINOMOTO CO., INC. (JP) | 2002-02-28 | — | — | US | disclosed |
| US-6222043-B1 | COUPLING 2-AMIDO-THIAZOLE DERIVATIVE WITH 2-PHENYL4-(PROTECTED)AMINO-BUTYRIC ACID; DEPROTECTING AMINO PROTECTING GROUP; ACYLATING PRODUCT WITH CARBOXYLIC ACID CONTAINING CARBOCYCLIC OR HETEROCYCLIC GROUP; DEPROTECTING | JAPAN ENERGY CORPORATION (JP) | 2001-04-24 | — | — | US | disclosed |
| US-6087530-A | Process for preparing β-amino-α-hydroxy acid derivatives | KANEKA CORPORATION (JP) | 2000-07-11 | — | — | US | disclosed |
| US-6020518-A | Process for preparing β-amino-α-hydroxy acid derivatives | KANEKA CORPORATION (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0930292-A1 | PROCESS FOR PREPARING $g(b)-AMINO-$g(a)-HYDROXY ACID DERIVATIVES | KANEKA CORPORATION (JP) | 1999-07-21 | — | — | EP | disclosed |
| EP-0574135-B1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORP (JP) | 1998-11-18 | — | — | EP | disclosed |
| US-5644028-A | Process for producing peptide derivatives and salts therefor | JAPAN ENERGY CORPORATION (JP) | 1997-07-01 | — | — | US | disclosed |
| US-5581007-A | Process for preparing optically active allophenylnorstatin derivatives | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1996-12-03 | — | — | US | disclosed |
| EP-0729939-A2 | Process for preparing optically active allophenylnorstatin derivatives, and intermediates for use therein | Takasago International Corporation (JP) | 1996-09-04 | — | — | EP | disclosed |
| EP-0574135-A1 | Process for producing peptide derivatives and salts thereof | JAPAN ENERGY CORPORATION (JP) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | KLK5 230/4885ATM 3773/4885ACE 15/4885 |
| US-20070066664-A1 | HIV PROTEASE INHIBITORS, COMPOSITIONS CONTAINING THE SAME, THEIR PHARMACEUTICAL USES, MATERIALS FOR THEIR SYNTHESIS | SERPINB1, PEPD, PREP | KLK5 216/4885ATM 3814/4885ACE 14/4885 |
| US-20020026081-A1 | Process for producing alpha-aminoketone derivatives | AADAT, BCKDK, BCAT1 | KLK5 665/4885ATM 2309/4885ACE 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.